TGFB1 and neoplasm: Specifically, TAMs inhibit T-cell activation and anti-tumor immune responses by secreting a series of cytokines and signaling molecules, such as IL-10 and TGF-β, thereby promoting tumor escape and drug resistance (Ruffell and Coussens, 2015).